Characterisation of new monoclonal antibodies reacting with prions from both human and animal brain tissues

Henriette Cordes Hvass, Ann-Louise Bergström, Jakob Ohm, Henning Lauersen, Peter M. H. Heegaard

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Post-mortem diagnosis of transmissible spongiform encephalopaties (prion diseases) is primarily based on the detection of a protease resistant, misfolded disease associated isoform (PrPSc) of the prion protein (PrPc) on neuronal cells. These methods depend on antibodies directed aganinst PrPc and capable of reacting with PrpSc in situ (immunohistochemistry on nervous tissue sections) or with the unfolded form of the protein (western and paraffin embedded tissue (PET) blotting). Here, high-affinity monoclonal antibodies (mAbs 1.5D7, 1.6F4) were produced against synthetic PrP peptides in wild-type mice and used for western blotting and immunohistochemistry to detect several types of human prion-disease associated PrPSc, including sporadic Creutzfeldt-Jakob Disease (CJD) (subtypes MM1 and V"), familial CJD and Gerstmann-Sträussler-Scheinker (GSS) disease PrPSc as well as PrPSc of bovine spongiform encephalopathy (bovine brain), scrapie (ovine brain) and experimental scrapie in hamster and in mice. The antibodies were also used for PET-blotting in which PrPSc blotted from brain tissue sections onto a nitrocellulose membrane is visualized with antibodies after protease and denaturant treatment allowing the detection of protease resistant PrP forms (PrPRES) in situ). Monoclonal antibodies 1.5D7 and 1.6F4 were raised against the reported epitope (PrP153-165) of the commercial antibody 6H4. While 1.5D7 and 1.6F4 were completely inhibitable by Prp153-165, 6H4 was not, indicating that the specificity of 6H4 is not defined completely by PrP153 - 165. The two antibodies performed similarly to 6H4 in western blotting with human samples, but showed less reactivity and enhanced background staining with animal samples in this method. In immunohistochemistry 1.5D7 and 1.6F4 performed better than 6H4 suggesting that the binding affinity of 1.5D7 and 1.6F4 with native (aggregated) PrPSc in situ was higher than that of 6H4. On the other hand in PET-blotting, 6H4 reached the same level of reactivity as 1.5D7 and 1.6F4. This shows that 6H4 needs denatured PrpRES to reach maximal reactivity, confirming earlier results. As an exception, human PrPRES still reacted relatively poorly with 6H4 in PET-blotting, while 1.5D7 and 1.6F4 reacted well with PrPRES from most human CDJ types. Taken together this implies that the binding epitope of 1.5D7 and 1.6F4 is accessible in the aggregates of undenatured PrPSc (IHC) while the binding site of 6H4 is at least partly inaccessible. In techniques incorporating a denaturing and/or disaggregating step 6H4 showed good binding indicating increased accessibility of the binding site. An exception to this is human samples in PET-blotting suggesting that huPrPRES might not be as easily unfolded by denaturation as BSE and scrapie PrPRES. Also of interest was the ability of 1.5D7 and 1.6F4 to
Original languageEnglish
JournalJournal of Immunological Methods
Volume337
Issue number2
Pages (from-to)106-120
ISSN0022-1759
DOIs
Publication statusPublished - 2008

Cite this

Hvass, Henriette Cordes ; Bergström, Ann-Louise ; Ohm, Jakob ; Lauersen, Henning ; Heegaard, Peter M. H. / Characterisation of new monoclonal antibodies reacting with prions from both human and animal brain tissues. In: Journal of Immunological Methods. 2008 ; Vol. 337, No. 2. pp. 106-120.
@article{c633d6937e9f44d3896fd9c225229237,
title = "Characterisation of new monoclonal antibodies reacting with prions from both human and animal brain tissues",
abstract = "Post-mortem diagnosis of transmissible spongiform encephalopaties (prion diseases) is primarily based on the detection of a protease resistant, misfolded disease associated isoform (PrPSc) of the prion protein (PrPc) on neuronal cells. These methods depend on antibodies directed aganinst PrPc and capable of reacting with PrpSc in situ (immunohistochemistry on nervous tissue sections) or with the unfolded form of the protein (western and paraffin embedded tissue (PET) blotting). Here, high-affinity monoclonal antibodies (mAbs 1.5D7, 1.6F4) were produced against synthetic PrP peptides in wild-type mice and used for western blotting and immunohistochemistry to detect several types of human prion-disease associated PrPSc, including sporadic Creutzfeldt-Jakob Disease (CJD) (subtypes MM1 and V{"}), familial CJD and Gerstmann-Str{\"a}ussler-Scheinker (GSS) disease PrPSc as well as PrPSc of bovine spongiform encephalopathy (bovine brain), scrapie (ovine brain) and experimental scrapie in hamster and in mice. The antibodies were also used for PET-blotting in which PrPSc blotted from brain tissue sections onto a nitrocellulose membrane is visualized with antibodies after protease and denaturant treatment allowing the detection of protease resistant PrP forms (PrPRES) in situ). Monoclonal antibodies 1.5D7 and 1.6F4 were raised against the reported epitope (PrP153-165) of the commercial antibody 6H4. While 1.5D7 and 1.6F4 were completely inhibitable by Prp153-165, 6H4 was not, indicating that the specificity of 6H4 is not defined completely by PrP153 - 165. The two antibodies performed similarly to 6H4 in western blotting with human samples, but showed less reactivity and enhanced background staining with animal samples in this method. In immunohistochemistry 1.5D7 and 1.6F4 performed better than 6H4 suggesting that the binding affinity of 1.5D7 and 1.6F4 with native (aggregated) PrPSc in situ was higher than that of 6H4. On the other hand in PET-blotting, 6H4 reached the same level of reactivity as 1.5D7 and 1.6F4. This shows that 6H4 needs denatured PrpRES to reach maximal reactivity, confirming earlier results. As an exception, human PrPRES still reacted relatively poorly with 6H4 in PET-blotting, while 1.5D7 and 1.6F4 reacted well with PrPRES from most human CDJ types. Taken together this implies that the binding epitope of 1.5D7 and 1.6F4 is accessible in the aggregates of undenatured PrPSc (IHC) while the binding site of 6H4 is at least partly inaccessible. In techniques incorporating a denaturing and/or disaggregating step 6H4 showed good binding indicating increased accessibility of the binding site. An exception to this is human samples in PET-blotting suggesting that huPrPRES might not be as easily unfolded by denaturation as BSE and scrapie PrPRES. Also of interest was the ability of 1.5D7 and 1.6F4 to",
author = "Hvass, {Henriette Cordes} and Ann-Louise Bergstr{\"o}m and Jakob Ohm and Henning Lauersen and Heegaard, {Peter M. H.}",
year = "2008",
doi = "10.1016/j.jim.2008.07.004",
language = "English",
volume = "337",
pages = "106--120",
journal = "Journal of Immunological Methods",
issn = "0022-1759",
publisher = "Elsevier",
number = "2",

}

Characterisation of new monoclonal antibodies reacting with prions from both human and animal brain tissues. / Hvass, Henriette Cordes; Bergström, Ann-Louise; Ohm, Jakob; Lauersen, Henning; Heegaard, Peter M. H.

In: Journal of Immunological Methods, Vol. 337, No. 2, 2008, p. 106-120.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Characterisation of new monoclonal antibodies reacting with prions from both human and animal brain tissues

AU - Hvass, Henriette Cordes

AU - Bergström, Ann-Louise

AU - Ohm, Jakob

AU - Lauersen, Henning

AU - Heegaard, Peter M. H.

PY - 2008

Y1 - 2008

N2 - Post-mortem diagnosis of transmissible spongiform encephalopaties (prion diseases) is primarily based on the detection of a protease resistant, misfolded disease associated isoform (PrPSc) of the prion protein (PrPc) on neuronal cells. These methods depend on antibodies directed aganinst PrPc and capable of reacting with PrpSc in situ (immunohistochemistry on nervous tissue sections) or with the unfolded form of the protein (western and paraffin embedded tissue (PET) blotting). Here, high-affinity monoclonal antibodies (mAbs 1.5D7, 1.6F4) were produced against synthetic PrP peptides in wild-type mice and used for western blotting and immunohistochemistry to detect several types of human prion-disease associated PrPSc, including sporadic Creutzfeldt-Jakob Disease (CJD) (subtypes MM1 and V"), familial CJD and Gerstmann-Sträussler-Scheinker (GSS) disease PrPSc as well as PrPSc of bovine spongiform encephalopathy (bovine brain), scrapie (ovine brain) and experimental scrapie in hamster and in mice. The antibodies were also used for PET-blotting in which PrPSc blotted from brain tissue sections onto a nitrocellulose membrane is visualized with antibodies after protease and denaturant treatment allowing the detection of protease resistant PrP forms (PrPRES) in situ). Monoclonal antibodies 1.5D7 and 1.6F4 were raised against the reported epitope (PrP153-165) of the commercial antibody 6H4. While 1.5D7 and 1.6F4 were completely inhibitable by Prp153-165, 6H4 was not, indicating that the specificity of 6H4 is not defined completely by PrP153 - 165. The two antibodies performed similarly to 6H4 in western blotting with human samples, but showed less reactivity and enhanced background staining with animal samples in this method. In immunohistochemistry 1.5D7 and 1.6F4 performed better than 6H4 suggesting that the binding affinity of 1.5D7 and 1.6F4 with native (aggregated) PrPSc in situ was higher than that of 6H4. On the other hand in PET-blotting, 6H4 reached the same level of reactivity as 1.5D7 and 1.6F4. This shows that 6H4 needs denatured PrpRES to reach maximal reactivity, confirming earlier results. As an exception, human PrPRES still reacted relatively poorly with 6H4 in PET-blotting, while 1.5D7 and 1.6F4 reacted well with PrPRES from most human CDJ types. Taken together this implies that the binding epitope of 1.5D7 and 1.6F4 is accessible in the aggregates of undenatured PrPSc (IHC) while the binding site of 6H4 is at least partly inaccessible. In techniques incorporating a denaturing and/or disaggregating step 6H4 showed good binding indicating increased accessibility of the binding site. An exception to this is human samples in PET-blotting suggesting that huPrPRES might not be as easily unfolded by denaturation as BSE and scrapie PrPRES. Also of interest was the ability of 1.5D7 and 1.6F4 to

AB - Post-mortem diagnosis of transmissible spongiform encephalopaties (prion diseases) is primarily based on the detection of a protease resistant, misfolded disease associated isoform (PrPSc) of the prion protein (PrPc) on neuronal cells. These methods depend on antibodies directed aganinst PrPc and capable of reacting with PrpSc in situ (immunohistochemistry on nervous tissue sections) or with the unfolded form of the protein (western and paraffin embedded tissue (PET) blotting). Here, high-affinity monoclonal antibodies (mAbs 1.5D7, 1.6F4) were produced against synthetic PrP peptides in wild-type mice and used for western blotting and immunohistochemistry to detect several types of human prion-disease associated PrPSc, including sporadic Creutzfeldt-Jakob Disease (CJD) (subtypes MM1 and V"), familial CJD and Gerstmann-Sträussler-Scheinker (GSS) disease PrPSc as well as PrPSc of bovine spongiform encephalopathy (bovine brain), scrapie (ovine brain) and experimental scrapie in hamster and in mice. The antibodies were also used for PET-blotting in which PrPSc blotted from brain tissue sections onto a nitrocellulose membrane is visualized with antibodies after protease and denaturant treatment allowing the detection of protease resistant PrP forms (PrPRES) in situ). Monoclonal antibodies 1.5D7 and 1.6F4 were raised against the reported epitope (PrP153-165) of the commercial antibody 6H4. While 1.5D7 and 1.6F4 were completely inhibitable by Prp153-165, 6H4 was not, indicating that the specificity of 6H4 is not defined completely by PrP153 - 165. The two antibodies performed similarly to 6H4 in western blotting with human samples, but showed less reactivity and enhanced background staining with animal samples in this method. In immunohistochemistry 1.5D7 and 1.6F4 performed better than 6H4 suggesting that the binding affinity of 1.5D7 and 1.6F4 with native (aggregated) PrPSc in situ was higher than that of 6H4. On the other hand in PET-blotting, 6H4 reached the same level of reactivity as 1.5D7 and 1.6F4. This shows that 6H4 needs denatured PrpRES to reach maximal reactivity, confirming earlier results. As an exception, human PrPRES still reacted relatively poorly with 6H4 in PET-blotting, while 1.5D7 and 1.6F4 reacted well with PrPRES from most human CDJ types. Taken together this implies that the binding epitope of 1.5D7 and 1.6F4 is accessible in the aggregates of undenatured PrPSc (IHC) while the binding site of 6H4 is at least partly inaccessible. In techniques incorporating a denaturing and/or disaggregating step 6H4 showed good binding indicating increased accessibility of the binding site. An exception to this is human samples in PET-blotting suggesting that huPrPRES might not be as easily unfolded by denaturation as BSE and scrapie PrPRES. Also of interest was the ability of 1.5D7 and 1.6F4 to

U2 - 10.1016/j.jim.2008.07.004

DO - 10.1016/j.jim.2008.07.004

M3 - Journal article

VL - 337

SP - 106

EP - 120

JO - Journal of Immunological Methods

JF - Journal of Immunological Methods

SN - 0022-1759

IS - 2

ER -